°£¾Ï Áø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : °Ë»ç À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2033³â)
Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type, By End-use, By Region And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1813988
¸®¼­Ä¡»ç : Grand View Research
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,431,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,848,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,683,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÀÚȸ»ç Æ÷ÇÔ)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°£¾Ï Áø´Ü ½ÃÀå ¿ä¾à

¼¼°èÀÇ °£¾Ï Áø´Ü ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 99¾ï 9,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2033³â¿¡´Â 175¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2033³â±îÁöÀÇ CAGRÀº 6.42%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

°£¾ÏÀº ¼¼°è ¸ðµç Ä¡¸íÀûÀÎ Áúº´ Áß »ç¸Á ¿øÀÎÀÇ 1À§ÀÔ´Ï´Ù.

1980³â ÀÌÈÄ °£¾ÏÀÇ ÀÌȯÀ²Àº 3¹è·Î, »ç¸Á·üÀº ÀÌ ±â°£¿¡ 2¹è·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹¾ÏÇùȸ´Â 2025³â¿¡´Â »õ·Ó°Ô ¾à 4¸¸ 2,240¸íÀÇ È¯ÀÚ°¡ ¹ß»ýÇØ ¾à 3¸¸ 90¸íÀÌ »ç¸ÁÇÒ °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í °°ÀÌ ¼¼°èÀûÀÎ °£¾Ï À¯º´·üÀÇ »ó½ÂÀº À§Çè ¿äÀο¡ ´ëÇÑ Áö¼ÓÀûÀÎ ³ëÃâ°ú ÇÔ²² ½ºÅ©¸®´×°ú Áø´Ü ½ÃÀåÀÇ ¼ºÀåÀ» ÇöÀúÇÏ°Ô °¡¼Ó½Ãų °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. °£¾ÏÀÇ ÀÌȯÀ² »ó½ÂÀº Á¶±â ¾Ï Áø´Ü°ú °ü·ÃµÈ À§Çè ÀÎÀÚ¸¦ ÁÙÀÌ´Â ³ë·Â¿¡ ´ëÇÑ ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. Á¶±â ¹ß°ßÀº ƯÈ÷ È¿°úÀûÀÎ °ËÁø ÇÁ·Î±×·¥À» ÅëÇØ ¾Ï°ú °ü·ÃµÈ »ç¸ÁÀ» ÁÙÀÌ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ÀüüÀûÀ¸·Î ¾ÏÀ» Á¶±â¿¡ Áø´ÜÇÏ´Â °ÍÀº ¹ß°ßÀÌ Áö¿¬µÇ´Â °Í¿¡ ºñÇØ ȯÀÚÀÇ »ýÁ¸À²À» 5¹è¿¡¼­ 10¹è ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù.

¼¼°èÀûÀ¸·Î °£¾Ï ȯÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Á¶±â ¹ß°ß µµ±¸¿Í ½ºÅ©¸®´× ¹æ¹ý¿¡ ´ëÇÑ Çʿ伺ÀÌ Ä¿Áö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ¹Ì±¹ ±¹¸³¾Ï¿¬±¸¼Ò´Â 2025³â 4¿ù ¹Ù´ÃÈíÀμ¼Æ÷Áø°ú °æ°æ°ü °£ »ý°Ë µîÀÇ ±â¼úÀ» Ȱ¿ëÇÑ °£(°£¼¼Æ÷)¾Ï ½ºÅ©¸®´×(PDQ)-ÀÇ·á Á¾»çÀÚÆÇ ÇÁ·Î±×·¥À» ¼³¸³Çß½À´Ï´Ù. ¸¸¼º °£ÁúȯÀÚ¿Í °°Àº °íÀ§Ç豺¿¡ ÃÊÁ¡À» ¸ÂÃá ÇÁ·Î±×·¥Àº ÃÊÀ½ÆÄ °Ë»ç, CT ½ºÄµ, Ç÷¾× °Ë»ç µîÀÇ Áø´Ü µµ±¸ÀÇ ÀÎÁöµµ Çâ»ó°ú ÀÌ¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¶±â ¹× Á¤±âÀûÀÎ ½ºÅ©¸®´×Àº ¹ß°ß·ü°ú ȯÀÚ °á°ú¸¦ °³¼±ÇÕ´Ï´Ù. ÀÌ¿Í °°ÀÌ ¿¹¹æ°ú Á¶±âÁø´ÜÀÌ Áß½ÃµÇ°Ô µÇ¸é¼­ °£¾Ï Áø´ÜÀÇ ±â¼ú Çõ½ÅÀÌ ÃËÁøµÇ¾î ½ÃÀå ¼ºÀåÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

ÇöÀç °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ´Â ÃÖ÷´ÜÀÇ Á¶±â ½ºÅ©¸®´× ±â¼ú ´öºÐ¿¡, °£¾ÏÀÇ ½ºÅ©¸®´×°ú Ä¡·á´Â Å« Àüȯ±â¸¦ ¸ÂÀÌÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »õ·Î¿î ±â¼ú Çõ½ÅÀÌ °£¾Ï Áø´Ü ½ÃÀåÀÇ ¼ºÀå¿¡ ±æÀ» ¿­°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2025³â 4¿ù, FDA´Â °íÀ§Çè °£°æº¯ ȯÀÚÀÇ °£¼¼Æ÷¾Ï(HCC) ¸ð´ÏÅ͸µÀ» À§ÇÑ EvoLiver »ý°Ë °Ë»ç¿¡ ȹ±âÀûÀÎ ÀÇ·á±â±â ÁöÁ¤À» ÁÖ¾ú½À´Ï´Ù. ÀÌ °Ë»ç´Â ¼¼Æ÷ ¿Ü ¼ÒÆ÷(EV) ±â¹Ý multiomics ¹ÙÀÌ¿À ¸¶Ä¿ ¼­¸íÀ» »ç¿ë ÇÏ ¿© Á¶±â °£¼¼Æ÷ ¾ÏÀÇ °ËÃâ¿¡ À¯¸ÁÇÑ °á°ú¸¦ º¸¿©ÁÝ´Ï´Ù. ȯÀÚ 464 °Ëü¸¦ ´ë»óÀ¸·Î ÇÑ MEV01 ½ÃÇèÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é, EvoLiver °Ë»ç´Â Á¶±â °£¼¼Æ÷¾ÏÀÇ °ËÃâ¿¡ À־ °¨µµ 86%, ƯÀ̵µ 88%¶ó´Â °æÀÌÀûÀÎ °á°ú¸¦ ³ªÅ¸³Â½À´Ï´Ù. ÀÌ °á°ú´Â ÃÊÀ½ÆÄ°Ë»ç³ª ¥á-ÆäÅä´Ü¹é°Ë»ç¿Í °°Àº ÇöÀçÀÇ °¨½Ã¹ýÀ» Å©°Ô ¿ôµµ´Â °ÍÀÔ´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ Á¢±Ù¹ýÀº °£°æº¯ ȯÀÚÀÇ °£¼¼Æ÷ ¾Ï °ü¸®¸¦ Å©°Ô Çâ»ó½Ãų °¡´É¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °£¾Ï Áø´Ü ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå °£¾Ï Áø´Ü ½ÃÀå : °Ë»ç À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå °£¾Ï Áø´Ü ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå °£¾Ï Áø´Ü ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Liver Cancer Diagnostics Market Summary

The global liver cancer diagnostics market size was estimated at USD 9.99 billion in 2024 and is projected to reach USD 17.57 billion by 2033, growing at a CAGR of 6.42% from 2025 to 2033. Liver cancer is the leading cause of death amongst all deadly diseases in the globe.

Since 1980, the rate of incidence of liver cancer has tripled and death rates have doubled during this period. The American Cancer Society estimated that in 2025, about 42,240 new cases are expected, and about 30,090 people will succumb to death. Thus, the global rise in liver cancer prevalence, combined with ongoing exposure to risk factors, will significantly accelerate the growth of the screening and diagnosis market. The rising incidence of liver cancer is increasing the demand for early-stage cancer diagnosis and efforts to reduce associated risk factors. Early detection is crucial in lowering cancer-related deaths, especially through effective screening programs. Overall, diagnosing cancer early can boost patient survival rates by 5 to 10 times compared to later detection.

As the global cases of liver cancer grow, the need for early detection tools and screening methods has intensified. For instance, the National Cancer Institute established the Liver (Hepatocellular) Cancer Screening (PDQ)-health professional version program in April 2025, utilizing techniques like needle aspiration cytology and trans jugular liver biopsy. Programs focused on high-risk groups, such as those with chronic liver conditions, are promoting greater awareness and use of diagnostic tools like ultrasound, CT scans, and blood tests. Early and regular screenings improve detection rates and patient outcomes. This increased emphasis on prevention and early diagnosis is driving innovations in liver cancer diagnostics and accelerating market growth.

Liver cancer screening and treatment are poised for a major shift thanks to cutting-edge early screening technologies currently in advanced development stages. These new innovations are paving the way for growth in the liver diagnostics market. For instance, in April 2025, the FDA granted breakthrough device designation to the EvoLiver biopsy test for monitoring hepatocellular carcinoma (HCC) in patients with high-risk cirrhosis. The test uses a multiomics biomarker signature based on extracellular vesicles (EV) and has shown promising results in detecting early-stage HCC. Data from the MEV01 trial, which involved 464 patient samples, indicated that the EvoLiver test achieved an impressive 86% sensitivity and 88% specificity for early-stage HCC detection. These results significantly surpass current surveillance methods like ultrasound and alpha-fetoprotein testing. This innovative approach has the potential to improve the management of hepatocellular carcinoma in cirrhotic patients greatly.

Global Liver Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global liver cancer diagnostics market report on the basis of test type, end-use, and region:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Liver Cancer Diagnostics Market Variables, Trends & Scope

Chapter 4. Liver Cancer Diagnostics Market: Test type Estimates & Trend Analysis

Chapter 5. Liver Cancer Diagnostics Market: End Use Estimates & Trend Analysis

Chapter 6. Liver Cancer Diagnostics Market: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â